The relationship between serum levels of CX3C chemokine ligand 1, cyclooxygenase-1 and the degree of gastric mucosal injury in patients with chronic gastritis
10.3760/cma.j.cn115455-20231228-00635
- VernacularTitle:慢性胃炎患者血清CX3C趋化因子配体1、环氧酶-1水平与胃黏膜损伤程度的关系
- Author:
Duo WEI
1
;
Liyun ZHANG
Author Information
1. 延安大学咸阳医院消化内科，咸阳 712000
- Keywords:
Gastritis;
Gastric mucosal injury;
CX3C chemokine ligand 1;
Epoxidase-1
- From:
Chinese Journal of Postgraduates of Medicine
2024;47(12):1098-1103
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the relationship between serum levels of CX3C chemokine ligand 1 (CX3CL1), cyclooxygenase-1 (COX-1) and the degree of gastric mucosal damage in patients with chronic gastritis.Methods:One hundred and fifty patients with chronic gastritis admitted to Yan′an University, Xianyang Hospital from September 2021 to September 2023 were in the study group, and another 100 healthy patients who underwent physical examination during the same period were selected as the control group. And 100 patients with chronic gastritis were divided into stages Ⅰ, Ⅱ, Ⅲ, and Ⅳ according to intestinal metaplasia (OLGIM) staging, and into mild, moderate, and severe according to atrophy (OLGA) grading; the levels of CX3CL1 and COX-1 in each group were compared, the correlation between CX3CL1, COX-1 levels and the degree of gastric mucosal injury in patients were analyzed, the predictive value of combined detection of CX3CL1 and COX-1 levels for the degree of gastric mucosal injury in patients with chronic gastritis were analyzed.Results:The levels of CX3CL1 and COX-1 in the study group were higher than those in the control group: (155.34 ± 12.11) ng/L vs. (95.47 ± 7.35) ng/L, (19.51 ± 1.50) μg/L vs. (12.35 ± 1.22) μg/L ( P<0.01); OLGA: compared with stage Ⅰ patients, the levels of COX-1 and CX3CL1 in stage Ⅱ and Ⅲ patients increased: (15.36 ± 1.29) μg/L and (18.66 ± 1.58) μg/L vs. (12.10 ± 1.16) μg/L, (124.19 ± 9.27) ng/L and (153.21 ± 12.19) ng/L vs. (93.28 ± 7.20) ng/L ( P<0.01); Compared with stage Ⅱ patients, stage Ⅲ patients have higher levels of COX-1 and CX3CL1 ( P<0.01). OLGIM: Compared with stage Ⅰ patients, the levels of CX3CL1 and COX-1 in stages Ⅱ, Ⅲ, and Ⅳ were elevated: (140.52 ± 11.15) ng/L, (149.37 ± 12.24) ng/L and (158.29 ± 13.31) ng/L vs. (92.82 ± 8.26) ng/L; (14.50 ± 1.32) μg/L, (18.22 ± 1.41) μg/L and (20.27 ± 1.60) μg/L vs. (12.16 ± 1.20) μg/L ( P<0.01); Compared with stage Ⅱ patients, the levels of COX-1 and CX3CL1 in stage Ⅲ and Ⅳ showed an increase ( P<0.01); Compared with stage Ⅲ patients, the levels of CX3CL1 and COX-1 in stage Ⅳ increased ( P<0.01); Compared with the control group, the levels of PGⅠ and PGⅠ/PGⅡ in the study group decreased: (39.35 ± 15.68) μg/L vs. (119.12 ± 17.36) μg/L, 2.77 ± 1.29 vs. 16.87 ± 1.09, while the levels of PGⅡ increased: (11.96 ± 7.05 vs 17.11 ± 15.95) μg/L. Pearson correlation analysis showed that the levels of CX3CL1 and COX-1 were positively correlated with the degree of gastric mucosal injury in patients ( P<0.01). The clinical value of combining CX3CL1 and COX-1 in predicting the degree of gastric mucosal damage in patients with chronic gastritis was significantly higher than that of single prediction ( P<0.01). Conclusions:The levels of serum CX3CL1 and COX-1 in chronic gastritis, and the two combined can evaluate the degree of gastric mucosa damage.
